Gene therapy upstart recruits more ex-AveXis talent; I-Mab reveals first-half results
It hasn’t been hard to see where Sean Nolan went looking for the talent needed to make Taysha into a leading player in the bustling gene therapy field.
Monday morning the company, where Nolan holds the chairman’s post, put out word that Taysha recruited the ex-CMO and ex-CFO at AveXis to come onto the board in the wake of a $94 million crossover raise.
In this environment, it’s yet another sign that Nolan and the top crew could have their sights set on an IPO as the biotech upstart completes the full team.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.